By: Bowers H.B. No. 1987
 
 
 
A BILL TO BE ENTITLED
 
AN ACT
  relating to the regulation of abortion, including abortion
  complication reporting and the repeal of certain laws prohibiting
  abortion.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  Sections 171.006(a) and (b), Health and Safety
  Code, as added by Chapter 4 (H.B. 13), Acts of the 85th Legislature,
  1st Called Session, 2017, are amended to read as follows:
         (a)  In this section, "abortion complication" means any
  harmful event or adverse outcome with respect to a patient related
  to an abortion that is performed on the patient and that is
  diagnosed or treated by a health care practitioner or at a health
  care facility and includes:
               (1)  shock;
               (2)  uterine perforation;
               (3)  cervical laceration;
               (4)  hemorrhage;
               (5)  aspiration or allergic response;
               (6)  infection;
               (7)  sepsis;
               (8)  death of the patient;
               (9)  incomplete abortion;
               (10)  damage to the uterus; or
               (11)  an infant born alive after the abortion
         (b)  The reporting requirements of this section apply only
  to:
               (1)  a physician who:
                     (A)  performs at an abortion facility an abortion
  that results in an abortion complication diagnosed or treated by
  that physician; or
                     (B)  diagnoses or treats at an abortion facility
  an abortion complication that is the result of an abortion
  performed by another physician at the facility; or
               (2)  a health care facility that is a hospital,
  abortion facility, freestanding emergency medical care facility,
  or health care facility that provides emergency medical care, as
  defined by Section 773.003.
         SECTION 2.  Section 171.061, Health and Safety Code, is
  amended by adding Subdivision (3) and amending Subdivision (8-a) to
  read as follows:
               (3)  "Final printed label" means the informational
  document approved by the United States Food and Drug Administration
  for an abortion-inducing drug that:
                     (A)  outlines the protocol authorized by that
  agency and agreed to by the drug company applying for authorization
  of the drug by that agency; and
                     (B)  delineates the manner in which a drug is to be
  used according to approval by that agency.
               (8-a) "Provide" means, as used with regard to
  abortion-inducing drugs, any act of giving, selling, dispensing,
  administering, or otherwise providing or prescribing an
  abortion-inducing drug.
         SECTION 3.  Section 171.063, Health and Safety Code, is
  amended by amending Subsections (a), (c), and (e) and adding
  Subsection (b) to read as follows:
         (a)  A person may not knowingly provide an abortion-inducing
  drug to a pregnant woman for the purpose of inducing an abortion in
  the pregnant woman or enabling another person to induce an abortion
  in the pregnant woman unless:
               (1)  the person who provides the abortion-inducing drug
  is a physician; and
               (2)  except as otherwise provided by Subsection (b),
  the provision of the abortion-inducing drug satisfies the protocol
  tested and authorized by the United States Food and Drug
  Administration as outlined in the final printed label of the
  abortion-inducing drug.
         (b)  A person may provide the abortion-inducing drug in the
  dosage amount prescribed by the clinical management guidelines
  defined by the American College of Obstetricians and Gynecologists
  Practice Bulletin as those guidelines existed on January 1, 2013.
         (c)  Before the physician provides an abortion-inducing
  drug, the physician must:
               (1)  examine the pregnant woman; and
               (2)  document, in the woman's medical record, the
  gestational age and intrauterine location of the pregnancy
         (d)  A physician who provides the abortion-inducing drug, or
  the physician's agent, must schedule a follow-up visit for the
  woman to occur not later than the 14th day after the administration
  or use of the abortion-inducing drug. At the follow-up visit, the
  physician must:
               (1)  confirm that the woman's pregnancy is completely
  terminated; and
               (2)  assess any continued blood loss.
         SECTION 4.  Section 171.206(b), Health and Safety Code, is
  amended to read as follows:
         (a)  This subchapter may not be construed to:
               (1)  authorize the initiation of a cause of action
  against or the prosecution of a woman on whom an abortion is
  performed or induced or attempted to be performed or induced in
  violation of this subchapter;
               (2)  wholly or partly repeal, either expressly or by
  implication, any other statute that regulates or prohibits
  abortion; or
               (3)  restrict a political subdivision from regulating
  or prohibiting abortion in a manner that is at least as stringent as
  the laws of this state.
         SECTION 5.  Section 171.207(b), Health and Safety Code, is
  amended to read as follows:
         (a)  Subsection (a) may not be construed to:
               (1)  legalize the conduct prohibited by this
  subchapter;
               (2)  limit in any way or affect the availability of a
  remedy established by Section 171.208; or
               (3)  limit the enforceability of any other laws that
  regulate or prohibit abortion.
         SECTION 6.  The following provisions are repealed:
               (1)  Chapter 170A, Health and Safety Code;
               (2)  Section 171.061(2-a), Health and Safety Code;
               (3)  Section 171.063(b-1), Health and Safety Code;
               (4)  Section 171.0631, Health and Safety Code;
               (5)  Section 171.0632, Health and Safety Code;
               (6)  Section 171.065, Health and Safety Code;
               (7)  Section 171.066, Health and Safety Code; and
               (8)  Chapter 6-1/2, Title 71, Revised Statutes.
         SECTION 7.  This Act takes effect September 1, 2025.